Please assess the completion status of the following clinical trial:

Trial Title: Prevention of GBS Colonization Via Immunity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participated in and completed the group B Streptococcus (GBS) Screening Protocol~* Non-pregnant women~* Aged 18-40 years at time of the screening protocol~* Currently sexually active at time of enrollment (sex with a male at least once in the last 4 months)~* Current use of effective birth control methods and stated intention to use the method for at least the next 30 days~* Provision of written informed consent~* Intention to stay in the geographical area for the next 18 months~* Access to telephone~Exclusion Criteria:~* Group B Streptococcus (GBS) positive by culture (vaginal and/or rectal), or culture positive for streptococcal strains that cross-react with GBS typing sera (vaginal and/or rectal).~* Pregnancy (all women will receive a urine pregnancy prior to vaccination).~* Any condition which in the opinion of the investigator would pose a health risk to the subject or interfere with the evaluation of the vaccine.~* Serious underlying disease, which is known at the time of vaccination (including: immunodeficiency, active or chronic hepatitis, immunosuppressive conditions which require systemic steroid therapy, or treatment for a malignancy during the past year).~* Receipt of any vaccine, blood product, or experimental medicine within the past 30 days with the exception of a licensed inactivated influenza vaccine.~* Plans to receive any vaccine, blood product, or experimental medicine in the next 30 days with the exception of a licensed inactivated influenza vaccine.~* Use of any antimicrobial agent(s) (vaginal or systemic) for treatment of any condition within 7 days prior to study enrollment (including: Monistat, Gyne-Lotrimin, et cetera )~* History of hypersensitivity to tetanus toxoid vaccine.~* Tetanus toxoid immunization within the previous 12 months.~* Previous participation in a study in which participants received tetanus toxoid vaccine or vaccine against Group B Streptococcus.~* Spontaneous or surgical menopause.~* Nursing mother.~* Hypersensitivity to thimerosal.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- GBS III-TT (Type: EXPERIMENTAL): A single dose of GBS III-TT vaccine administered intramuscularly (IM) containing 50 mcg of GBS III capsular polysaccharide and 32 mcg of tetanus toxoid.
- Td (Type: ACTIVE_COMPARATOR): The control group will receive a single dose of Tetanus and Diphtheria Toxoids (Td) vaccine.

Based on this trial design, predict the completion outcome and termination type (if applicable).